📋 Clinical Overview

Dehydroemetine is a synthetic derivative of emetine, an alkaloid from ipecac root. It is a potent anti-protozoal agent, primarily used as a second-line treatment for severe invasive intestinal and extra-intestinal amebiasis, particularly amebic liver abscess, when metronidazole or other nitroimidazoles are ineffective, contraindicated, or not tolerated. It acts by inhibiting protein synthesis in Entamoeba histolytica trophozoites. Due to its significant cardiotoxicity and neuromuscular toxicity, its use is highly restricted and requires strict hospital-based supervision.

💊 Dosage & Administration

Adult: 1 mg/kg body weight per day (not to exceed 60 mg/day) by deep intramuscular injection for 5-10 days. Maximum course duration is 10 days.

Note: Administer by DEEP INTRAMUSCULAR INJECTION into a large muscle mass (gluteus maximus). Rotate injection sites daily. NEVER administer intravenously or subcutaneously. Patient must be on complete bed rest or limited activity during and for several weeks after therapy to minimize cardiac stress.

⚠️ Contraindications

Known hypersensitivity to dehydroemetine or emetine
Pre-existing cardiac disease (e.g., cardiomyopathy, arrhythmias, heart failure)
Severe renal impairment
Severe hepatic impairment
Pregnancy
Myasthenia gravis or other neuromuscular disorders

🔬 Mechanism of Action

Dehydroemetine irreversibly inhibits protein synthesis in Entamoeba histolytica trophozoites. It binds to the 40S ribosomal subunit, blocking the translocation step of polypeptide chain elongation. This leads to the death of the invasive, tissue-dwelling form of the parasite.

🤕 Side Effects

Pain, tenderness, and sterile abscess at injection site
Muscle weakness, stiffness, or tenderness
Mild hypotension, tachycardia
Nausea, vomiting, diarrhea

🤰 Special Populations

Pregnancy: CONTRANDICATED. Category X. Emetine derivatives are embryotoxic and can cause fetal death or malformations.

Driving: Patients must NOT drive or operate heavy machinery during and for several weeks after therapy due to risks of dizziness, syncope, and muscle weakness.

🔄 Drug Interactions

Other cardiotoxic drugs (e.g., Chloroquine, Halofantrine, Arsenic trioxide)	Additive risk of QT prolongation and serious arrhythmias.	Major
Neuromuscular blocking agents	Enhanced neuromuscular blockade, leading to prolonged apnea.	Major
Diuretics (especially loop and thiazide diuretics)	Hypokalemia and hypomagnesemia increase risk of dehydroemetine-induced cardiotoxicity.	Major
Drugs causing bradycardia (e.g., Beta-blockers, Digoxin)	Additive effect on heart rate and conduction.	Moderate
CYP450 inhibitors/inducers	Potential to alter metabolism, though pathways are not fully defined. Monitor for toxicity or reduced efficacy.	Moderate

Mebadin